Verified ComparisonLast updated: 11 April 2026
Tesamorelin vs CJC-1295
Both modulate the GHRH axis. Their evidence bases — and regulatory status — diverge sharply.
Tesamorelin
GH Releasing
4.4/ 5
A
CJC-1295
GH Releasing
4.3/ 5
A−
Editor's note
Tesamorelin has a clear approved-indication evidence base. CJC-1295 sits firmly in research literature.
| Criterion | Tesamorelin | CJC-1295 |
|---|---|---|
| Mechanism | GHRH analog | GHRH analog (long-acting) |
| Approved indication | HIV-related lipodystrophy | None |
| Regulatory status (AU) | Prescriber pathways may apply | Not approved for human use |
| Half-life | Short | Long with DAC |
Frequently asked questions
No. One has an approved medical pathway and the other does not.
Want to read the full reviews?